Cargando…

Do endocannabinoids acting via hepatic CB-1 contribute to NAFLD and hepatic insulin resistance?

Detalles Bibliográficos
Autores principales:	Kunos, George, Jourdan, Tony, Tam, Joseph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718143/ https://www.ncbi.nlm.nih.gov/pubmed/34981780 http://dx.doi.org/10.1172/JCI155330

Ejemplares similares

Does CB-1 in hepatic stellate cells contribute to liver fibrosis?
por: Lotersztajn, Sophie, et al.
Publicado: (2022)

Alcohol Binge-Induced Cardiovascular Dysfunction Involves Endocannabinoid–CB1-R Signaling
por: Paloczi, Janos, et al.
Publicado: (2019)

Decreasing CB(1) receptor signaling in Kupffer cells improves insulin sensitivity in obese mice
por: Jourdan, Tony, et al.
Publicado: (2017)

CB(1)R regulates soluble leptin receptor levels via CHOP, contributing to hepatic leptin resistance
por: Drori, Adi, et al.
Publicado: (2020)

Structural basis for activation of CB1 by an endocannabinoid analog
por: Krishna Kumar, Kaavya, et al.
Publicado: (2023)

SUN-665 Peripheral CB(1)R Blocker Improves Metabolism in Diet Induced Obese Mice Independent of Hepatic FGF21
por: Liu, Jie, et al.
Publicado: (2020)

HFD and HFD-provoked hepatic hypoxia act as reciprocal causation for NAFLD via HIF-independent signaling
por: Zhang, Xiaofang, et al.
Publicado: (2020)

Cannabinoid receptor type 1 (CB(1)R) inhibits hypothalamic leptin signaling via β-arrestin1 in complex with TC-PTP and STAT3
por: Szanda, Gergő, et al.
Publicado: (2023)

Targeting the endocannabinoid/CB1 receptor system for treating obesity in Prader–Willi syndrome
por: Knani, Ibrahim, et al.
Publicado: (2016)

Endocannabinoid engagement of CB(2) regulates RSV-induced immunity
por: Kaplan, Barbara L. F.
Publicado: (2018)

To Act or Not to Act: Endocannabinoid/Dopamine Interactions in Decision-Making
por: Hernandez, Giovanni, et al.
Publicado: (2015)

Docosahexaenoic acid enrichment in NAFLD is associated with improvements in hepatic metabolism and hepatic insulin sensitivity: a pilot study
por: Hodson, L, et al.
Publicado: (2017)

Dysfunctional endocannabinoid CB1 receptor expression and signaling contribute to skeletal muscle cell toxicity induced by simvastatin
por: Kalkan, Hilal, et al.
Publicado: (2023)

Pharmacological characterization of the endocannabinoid sensor GRAB(eCB2.0)
por: Singh, Simar, et al.
Publicado: (2023)

Vaccination of Hepatitis A; To Do or Not to Do?
por: Allameh, Seyed Farshad, et al.
Publicado: (2017)

Biologically active, high levels of interleukin-22 inhibit hepatic gluconeogenesis but do not affect obesity and its metabolic consequences
por: Park, Ogyi, et al.
Publicado: (2015)

Fine-tuning of synaptic upscaling at excitatory synapses by endocannabinoid signaling is mediated via the CB1 receptor
por: Song, Yunping, et al.
Publicado: (2015)

Hepatic lipid droplets: A balancing act between energy storage and metabolic dysfunction in NAFLD
por: Mashek, Douglas G.
Publicado: (2020)

Erratum: Docosahexaenoic acid enrichment in NAFLD is associated with improvements in hepatic metabolism and hepatic insulin sensitivity: a pilot study
por: Hodson, L, et al.
Publicado: (2017)

Cannabinoid CB2 Receptor Potentiates Obesity-Associated Inflammation, Insulin Resistance and Hepatic Steatosis
por: Deveaux, Vanessa, et al.
Publicado: (2009)

Mechanisms underlying restoration of hepatic insulin sensitivity with CB1 antagonism in the obese dog model
por: Kim, Stella P.
Publicado: (2013)

Genetic and pharmacological regulation of the endocannabinoid CB1 receptor in Duchenne muscular dystrophy
por: Iannotti, Fabio A., et al.
Publicado: (2018)

Hepatic artery resistive index as surrogate marker for fibrosis progression in NAFLD patients: A clinical perspective
por: Tana, Claudio, et al.
Publicado: (2018)

Cholesterol as a modulator of cannabinoid receptor CB(2) signaling
por: Yeliseev, Alexei, et al.
Publicado: (2021)

Activation of Both CB1 and CB2 Endocannabinoid Receptors Is Critical for Masculinization of the Developing Medial Amygdala and Juvenile Social Play Behavior
por: Argue, Kathryn J, et al.
Publicado: (2017)

Follistatin Alleviates Hepatic Steatosis in NAFLD via the mTOR Dependent Pathway
por: Tong, Junlu, et al.
Publicado: (2022)

Functional Selectivity of a Biased Cannabinoid-1 Receptor (CB(1)R) Antagonist
por: Liu, Ziyi, et al.
Publicado: (2021)

Roles of the Hepatic Endocannabinoid and Apelin Systems in the Pathogenesis of Liver Fibrosis
por: Melgar-Lesmes, Pedro, et al.
Publicado: (2019)

Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD
por: Fourman, Lindsay T., et al.
Publicado: (2020)

Fluoxetine Facilitates Fear Extinction Through Amygdala Endocannabinoids
por: Gunduz-Cinar, Ozge, et al.
Publicado: (2016)

Tonic endocannabinoid-mediated modulation of GABA release is independent of the CB(1) content of axon terminals
por: Lenkey, Nora, et al.
Publicado: (2015)

Downregulation of the CB1-Mediated Endocannabinoid Signaling Underlies D-Galactose-Induced Memory Impairment
por: Li, Ranran, et al.
Publicado: (2020)

Angiotensin II-Induced Cardiac Effects Are Modulated by Endocannabinoid-Mediated CB(1) Receptor Activation
por: Miklós, Zsuzsanna, et al.
Publicado: (2021)

Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD
por: Takahashi, Hirokazu, et al.
Publicado: (2021)

Hepatic PEMT Expression Decreases with Increasing NAFLD Severity
por: Piras, Ignazio S., et al.
Publicado: (2022)

Maternal exercise conveys protection against NAFLD in the offspring via hepatic metabolic programming
por: Bae-Gartz, Inga, et al.
Publicado: (2020)

Reply to: ‘NAFLD or comorbidities, that is the question’
por: Ji, Dong, et al.
Publicado: (2020)

Repurposing Hepatitis C Direct-Acting Antivirals Against COVID-19
por: Kumar, Pramod, et al.
Publicado: (2021)

Central Endocannabinoid Signaling Regulates Hepatic Glucose Production and Systemic Lipolysis
por: O’Hare, James D., et al.
Publicado: (2011)

Endocannabinoid System in Hepatic Glucose Metabolism, Fatty Liver Disease, and Cirrhosis
por: Bazwinsky-Wutschke, Ivonne, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_olfbeuvcg24902v6p4227ab9ca